Global Immune Checkpoint Inhibitors Market Research Report 2021
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
Research Predicts that Immune Checkpoint Inhibitors Market was valued USD xxxx unit in 2020 and is expected to reach USD xxxx Unit by the year 2025, growing at a CAGR of xx% globally.
Global Immune Checkpoint Inhibitors Market Overview:
Global Immune Checkpoint Inhibitors Market Report 2020 comes with the extensive industry analysis of development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2020-2025.This research study of Immune Checkpoint Inhibitors involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Impact of COVID-19 on Immune Checkpoint Inhibitors Market
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affected the Immune Checkpoint Inhibitors market in 2020.
Global Immune Checkpoint Inhibitors Market Segmentation
By Type, Immune Checkpoint Inhibitors market has been segmented into:
PD-1/PD-L1
CTLA-4
By Application, Immune Checkpoint Inhibitors market has been segmented into:
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
Asia-Pacific (China, India, Japan, Southeast Asia etc.)
South America (Brazil, Argentina etc.)
Middle East & Africa (Saudi Arabia, South Africa etc.)
Top Key Players Covered in Immune Checkpoint Inhibitors market are:
Bristol Myer Squibb
AstraZeneca
Merck & Co.
Roche / Genentech Incyte Corporation
NewLink Genetics
ArGEN-X
Seattle Genetics
Pfizer
MacroGenics
Celldex Therapeutics
CureTech
Immutep
Innate Pharma
Sorrento Therapeutics
GlaxoSmithKline
GITR Inc
1. Market Overview of Immune Checkpoint Inhibitors
1.1 Immune Checkpoint Inhibitors Market Overview
1.1.1 Immune Checkpoint Inhibitors Product Scope
1.1.2 Market Status and Outlook
1.2 Immune Checkpoint Inhibitors Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Immune Checkpoint Inhibitors Historic Market Size by Regions (2015-2020)
1.4 Immune Checkpoint Inhibitors Forecasted Market Size by Regions (2021-2026)
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth (2015-2026)
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Immune Checkpoint Inhibitors Sales Market by Type (2015-2026)
2.1 Global Immune Checkpoint Inhibitors Historic Market Size by Type (2015-2020)
2.2 Global Immune Checkpoint Inhibitors Forecasted Market Size by Type (2021-2026)
2.3 PD-1/PD-L1
2.4 CTLA-4
3. Covid-19 Impact Immune Checkpoint Inhibitors Sales Market by Application (2015-2026)
3.1 Global Immune Checkpoint Inhibitors Historic Market Size by Application (2015-2020)
3.2 Global Immune Checkpoint Inhibitors Forecasted Market Size by Application (2021-2026)
3.3 Lung Cancer
3.4 Colorectal Cancer
3.5 Breast Cancer
3.6 Prostate Cancer
3.7 Melanoma
3.8 Blood Cancer
3.9 Others
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Immune Checkpoint Inhibitors Production Capacity Market Share by Manufacturers (2015-2020)
4.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Manufacturers (2015-2020)
4.3 Global Immune Checkpoint Inhibitors Average Price by Manufacturers (2015-2020)
5. Company Profiles and Key Figures in Immune Checkpoint Inhibitors Business
5.1 Bristol Myer Squibb
5.1.1 Bristol Myer Squibb Company Profile
5.1.2 Bristol Myer Squibb Immune Checkpoint Inhibitors Product Specification
5.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.2 AstraZeneca
5.2.1 AstraZeneca Company Profile
5.2.2 AstraZeneca Immune Checkpoint Inhibitors Product Specification
5.2.3 AstraZeneca Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.3 Merck & Co.
5.3.1 Merck & Co. Company Profile
5.3.2 Merck & Co. Immune Checkpoint Inhibitors Product Specification
5.3.3 Merck & Co. Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.4 Roche / Genentech Incyte Corporation
5.4.1 Roche / Genentech Incyte Corporation Company Profile
5.4.2 Roche / Genentech Incyte Corporation Immune Checkpoint Inhibitors Product Specification
5.4.3 Roche / Genentech Incyte Corporation Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.5 NewLink Genetics
5.5.1 NewLink Genetics Company Profile
5.5.2 NewLink Genetics Immune Checkpoint Inhibitors Product Specification
5.5.3 NewLink Genetics Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.6 ArGEN-X
5.6.1 ArGEN-X Company Profile
5.6.2 ArGEN-X Immune Checkpoint Inhibitors Product Specification
5.6.3 ArGEN-X Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.7 Seattle Genetics
5.7.1 Seattle Genetics Company Profile
5.7.2 Seattle Genetics Immune Checkpoint Inhibitors Product Specification
5.7.3 Seattle Genetics Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.8 Pfizer
5.8.1 Pfizer Company Profile
5.8.2 Pfizer Immune Checkpoint Inhibitors Product Specification
5.8.3 Pfizer Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.9 MacroGenics
5.9.1 MacroGenics Company Profile
5.9.2 MacroGenics Immune Checkpoint Inhibitors Product Specification
5.9.3 MacroGenics Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.10 Celldex Therapeutics
5.10.1 Celldex Therapeutics Company Profile
5.10.2 Celldex Therapeutics Immune Checkpoint Inhibitors Product Specification
5.10.3 Celldex Therapeutics Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.11 CureTech
5.11.1 CureTech Company Profile
5.11.2 CureTech Immune Checkpoint Inhibitors Product Specification
5.11.3 CureTech Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.12 Immutep
5.12.1 Immutep Company Profile
5.12.2 Immutep Immune Checkpoint Inhibitors Product Specification
5.12.3 Immutep Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.13 Innate Pharma
5.13.1 Innate Pharma Company Profile
5.13.2 Innate Pharma Immune Checkpoint Inhibitors Product Specification
5.13.3 Innate Pharma Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.14 Sorrento Therapeutics
5.14.1 Sorrento Therapeutics Company Profile
5.14.2 Sorrento Therapeutics Immune Checkpoint Inhibitors Product Specification
5.14.3 Sorrento Therapeutics Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.15 GlaxoSmithKline
5.15.1 GlaxoSmithKline Company Profile
5.15.2 GlaxoSmithKline Immune Checkpoint Inhibitors Product Specification
5.15.3 GlaxoSmithKline Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.16 GITR Inc
5.16.1 GITR Inc Company Profile
5.16.2 GITR Inc Immune Checkpoint Inhibitors Product Specification
5.16.3 GITR Inc Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
6. North America
6.1 North America Immune Checkpoint Inhibitors Market Size (2015-2026)
6.2 North America Immune Checkpoint Inhibitors Key Players in North America (2015-2020)
6.3 North America Immune Checkpoint Inhibitors Market Size by Type (2015-2020)
6.4 North America Immune Checkpoint Inhibitors Market Size by Application (2015-2020)
7. East Asia
7.1 East Asia Immune Checkpoint Inhibitors Market Size (2015-2026)
7.2 East Asia Immune Checkpoint Inhibitors Key Players in North America (2015-2020)
7.3 East Asia Immune Checkpoint Inhibitors Market Size by Type (2015-2020)
7.4 East Asia Immune Checkpoint Inhibitors Market Size by Application (2015-2020)
8. Europe
8.1 Europe Immune Checkpoint Inhibitors Market Size (2015-2026)
8.2 Europe Immune Checkpoint Inhibitors Key Players in North America (2015-2020)
8.3 Europe Immune Checkpoint Inhibitors Market Size by Type (2015-2020)
8.4 Europe Immune Checkpoint Inhibitors Market Size by Application (2015-2020)
9. South Asia
9.1 South Asia Immune Checkpoint Inhibitors Market Size (2015-2026)
9.2 South Asia Immune Checkpoint Inhibitors Key Players in North America (2015-2020)
9.3 South Asia Immune Checkpoint Inhibitors Market Size by Type (2015-2020)
9.4 South Asia Immune Checkpoint Inhibitors Market Size by Application (2015-2020)
10. Southeast Asia
10.1 Southeast Asia Immune Checkpoint Inhibitors Market Size (2015-2026)
10.2 Southeast Asia Immune Checkpoint Inhibitors Key Players in North America (2015-2020)
10.3 Southeast Asia Immune Checkpoint Inhibitors Market Size by Type (2015-2020)
10.4 Southeast Asia Immune Checkpoint Inhibitors Market Size by Application (2015-2020)
11. Middle East
11.1 Middle East Immune Checkpoint Inhibitors Market Size (2015-2026)
11.2 Middle East Immune Checkpoint Inhibitors Key Players in North America (2015-2020)
11.3 Middle East Immune Checkpoint Inhibitors Market Size by Type (2015-2020)
11.4 Middle East Immune Checkpoint Inhibitors Market Size by Application (2015-2020)
12. Africa
12.1 Africa Immune Checkpoint Inhibitors Market Size (2015-2026)
12.2 Africa Immune Checkpoint Inhibitors Key Players in North America (2015-2020)
12.3 Africa Immune Checkpoint Inhibitors Market Size by Type (2015-2020)
12.4 Africa Immune Checkpoint Inhibitors Market Size by Application (2015-2020)
13. Oceania
13.1 Oceania Immune Checkpoint Inhibitors Market Size (2015-2026)
13.2 Oceania Immune Checkpoint Inhibitors Key Players in North America (2015-2020)
13.3 Oceania Immune Checkpoint Inhibitors Market Size by Type (2015-2020)
13.4 Oceania Immune Checkpoint Inhibitors Market Size by Application (2015-2020)
14. South America
14.1 South America Immune Checkpoint Inhibitors Market Size (2015-2026)
14.2 South America Immune Checkpoint Inhibitors Key Players in North America (2015-2020)
14.3 South America Immune Checkpoint Inhibitors Market Size by Type (2015-2020)
14.4 South America Immune Checkpoint Inhibitors Market Size by Application (2015-2020)
15. Rest of the World
15.1 Rest of the World Immune Checkpoint Inhibitors Market Size (2015-2026)
15.2 Rest of the World Immune Checkpoint Inhibitors Key Players in North America (2015-2020)
15.3 Rest of the World Immune Checkpoint Inhibitors Market Size by Type (2015-2020)
15.4 Rest of the World Immune Checkpoint Inhibitors Market Size by Application (2015-2020)
16 Immune Checkpoint Inhibitors Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter’s Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer
Research Methodology:
Immune Checkpoint Inhibitors Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|